Changzhou Qianhong Biopharma Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHE:002550
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 729 out of 853
Universe
Global Universe 13231 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Collegium Pharmaceutical, Inc. |
29.4
Medium
|
405 out of 853 |
Procter & Gamble Health Ltd. |
32.8
High
|
556 out of 853 |
Caregen Co., Ltd. |
35
High
|
653 out of 853 |
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. |
36.5
High
|
721 out of 853 |
Changzhou Qianhong Biopharma Co., Ltd. |
36.8
High
|
729 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Changzhou Qianhong Biopharma Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Changzhou Qianhong Biopharma Co., Ltd.'s Management of ESG Material Risk is Average